Diabetes, Vol 44, Issue 2 185-189, Copyright © 1995 by American Diabetes Association

ARTICLES

Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration

I Magnusson, DL Rothman, DP Gerard, LD Katz and GI Shulman
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8020.

The contribution of net hepatic glycogenolysis to overall glucose production during a physiological increment in the plasma glucagon concentration was measured in six healthy subjects (18-24 years, 68-105 kg) after an overnight fast. Glucagon (approximately 3 ng.kg-1.min-1), somatostatin (0.1 microgram.kg-1.min-1), and insulin (0.9 pmol.kg-1.min-1) were infused for 3 h. Liver glycogen concentration was measured at 15-min intervals during this period using 13C-labeled nuclear magnetic resonance spectroscopy, and liver volume was assessed from magnetic resonance images. The rate of net hepatic glycogenolysis was calculated from the decrease in liver glycogen concentration over time, multiplied by the liver volume. The rate of glucose appearance (Ra) was calculated from [3-3H]glucose turnover data using a two-compartment model of glucose kinetics. Plasma glucagon concentration rose from 136 +/- 18 to 304 +/- 57 ng/l and plasma glucose concentration rose from 5.6 +/- 0.1 to 10.4 +/- 0.9 mmol/l on initiation of the infusions. Mean baseline Ra was 11.8 +/- 0.4 mumol.kg-1.min-1, increased rapidly after the beginning of the infusions, reaching its highest value after 20-40 min, and returned to baseline by 140 min. Liver glycogen concentration decreased almost linearly (from 300 +/- 19 mmol/l liver at baseline to 192 +/- 20 mmol/l liver at t = 124 min) during 2 h after the beginning of the infusions, and the calculated mean rate of net hepatic glycogenolysis was 21.7 +/- 3.6 mumol.kg-1.min-1. Mean Ra during the same time period was 22.8 +/- 2.3 mumol.kg-1.min-1. Thus, net hepatic glycogenolysis accounted for 93 +/- 9% of Ra.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Hiroyama, T. Aoyagi, Y. Fujiwara, S. Oshikawa, A. Sanbe, F. Endo, and A. Tanoue Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume J. Physiol., June 15, 2007; 581(3): 1183 - 1192. [Abstract] [Full Text] [PDF]

				B. E. Dunning and J. E. Gerich The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications Endocr. Rev., May 1, 2007; 28(3): 253 - 283. [Abstract] [Full Text] [PDF]

				M. Z. Strowski, D. E. Cashen, E. T. Birzin, L. Yang, V. Singh, T. M. Jacks, K. W. Nowak, S. P. Rohrer, A. A. Patchett, R. G. Smith, et al. Antidiabetic Activity of a Highly Potent and Selective Nonpeptide Somatostatin Receptor Subtype-2 Agonist Endocrinology, October 1, 2006; 147(10): 4664 - 4673. [Abstract] [Full Text] [PDF]

				C. Everett-Grueter, D. S. Edgerton, E. P. Donahue, S. Vaughan, C. A. Chu, D. K. Sindelar, and A. D. Cherrington The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E449 - E459. [Abstract] [Full Text] [PDF]

				P. Kishore, I. Gabriely, M.-H. Cui, J. Di Vito, S. Gajavelli, J.-H. Hwang, and H. Shamoon Role of Hepatic Glycogen Breakdown in Defective Counterregulation of Hypoglycemia in Intensively Treated Type 1 Diabetes Diabetes, March 1, 2006; 55(3): 659 - 666. [Abstract] [Full Text] [PDF]

				K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, S. Vaughan, E. P. Donahue, P. Flakoll, and A. D. Cherrington Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E534 - E544. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, E. P. Donahue, P. Flakoll, and A. D. Cherrington Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E695 - E707. [Abstract] [Full Text] [PDF]

				G. Boden, P. Cheung, T. P. Stein, K. Kresge, and M. Mozzoli FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E12 - E19. [Abstract] [Full Text] [PDF]

				M. G. Bischof, E. Bernroider, M. Krssak, M. Krebs, H. Stingl, P. Nowotny, C. Yu, G. I. Shulman, W. Waldhausl, and M. Roden Hepatic Glycogen Metabolism in Type 1 Diabetes After Long-Term Near Normoglycemia Diabetes, January 1, 2002; 51(1): 49 - 54. [Abstract] [Full Text] [PDF]

				M. W. Haymond and B. Schreiner Mini-Dose Glucagon Rescue for Hypoglycemia in Children With Type 1 Diabetes Diabetes Care, April 1, 2001; 24(4): 643 - 645. [Abstract] [Full Text]

				M. G. Bischof, M. Krssak, M. Krebs, E. Bernroider, H. Stingl, W. Waldhäusl, and M. Roden Effects of Short-Term Improvement of Insulin Treatment and Glycemia on Hepatic Glycogen Metabolism in Type 1 Diabetes Diabetes, February 1, 2001; 50(2): 392 - 398. [Abstract] [Full Text]

				P. Shah, A. Vella, A. Basu, R. Basu, W. F. Schwenk, and R. A. Rizza Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4053 - 4059. [Abstract] [Full Text]

				A. Balasubramanyam, S. McKay, P. Nadkarni, A. S. Rajan, A. Garza, V. Pavlik, J. A. Herd, F. Jahoor, and P. J. Reeds Ethnicity affects the postprandial regulation of glycogenolysis Am J Physiol Endocrinol Metab, November 1, 1999; 277(5): E905 - E914. [Abstract] [Full Text] [PDF]

				I. Nissim, M. E. Brosnan, M. Yudkoff, I. Nissim, and J. T. Brosnan Studies of Hepatic Glutamine Metabolism in the Perfused Rat Liver with 15N-Labeled Glutamine J. Biol. Chem., October 8, 1999; 274(41): 28958 - 28965. [Abstract] [Full Text] [PDF]

				P. Shah, A. Basu, R. Basu, and R. Rizza Impact of lack of suppression of glucagon on glucose tolerance in humans Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E283 - E290. [Abstract] [Full Text] [PDF]

				R. Drouin, C. Lavoie, J. Bourque, F. Ducros, D. Poisson, and J.-L. Chiasson Increased hepatic glucose production response to glucagon in trained subjects Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E23 - E28. [Abstract] [Full Text] [PDF]

				C. A. Chu, D. K. Sindelar, D. W. Neal, E. J. Allen, E. P. Donahue, and A. D. Cherrington Effect of a selective rise in sinusoidal norepinephrine on HGP is due to an increase in glycogenolysis Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E162 - E171. [Abstract] [Full Text] [PDF]